Evercore Wealth Management Boosted By $24.47 Million Its Blackrock (BLK) Holding; Juno Therapeutics (JUNO) Had 6 Analysts Last Week

August 27, 2017 - By Henry Gaston

Among 15 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 6 have Buy rating, 1 Sell and 8 Hold. Therefore 40% are positive. Juno Therapeutics Inc had 29 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, June 2 by Raymond James. Suntrust Robinson downgraded Juno Therapeutics Inc (NASDAQ:JUNO) on Friday, November 25 to “Hold” rating. On Wednesday, November 18 the stock rating was initiated by Goldman Sachs with “Neutral”. The firm has “Buy” rating given on Friday, January 29 by Suntrust Robinson. Barclays Capital initiated it with “Equal-Weight” rating and $48 target in Wednesday, July 6 report. Maxim Group maintained the shares of JUNO in report on Wednesday, November 23 with “Buy” rating. The firm has “Neutral” rating given on Friday, July 8 by JP Morgan. The firm has “Buy” rating by Citigroup given on Thursday, February 25. The company was maintained on Friday, August 5 by Maxim Group. FBR Capital initiated Juno Therapeutics Inc (NASDAQ:JUNO) rating on Tuesday, August 18. FBR Capital has “Outperform” rating and $73 target. See Juno Therapeutics Inc (NASDAQ:JUNO) latest ratings:

07/08/2017 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $26 New Target: $27 Maintain
08/06/2017 Broker: BTIG Research Old Rating: Neutral New Rating: Sell Downgrade
30/05/2017 Broker: Standpoint Research Rating: Buy

Evercore Wealth Management Llc increased Blackrock Inc (BLK) stake by 1053.54% reported in 2016Q4 SEC filing. Evercore Wealth Management Llc acquired 64,403 shares as Blackrock Inc (BLK)’s stock rose 1.17%. The Evercore Wealth Management Llc holds 70,516 shares with $26.83M value, up from 6,113 last quarter. Blackrock Inc now has $67.03 billion valuation. The stock increased 0.10% or $0.43 on August 25, reaching $416.37. About 466,698 shares traded. BlackRock, Inc. (NYSE:BLK) has risen 12.19% since August 27, 2016 and is uptrending. It has underperformed by 4.51% the S&P500.

The stock increased 1.35% or $0.41 on August 25, reaching $30.73. About 2.16 million shares traded or 74.19% up from the average. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 39.85% since August 27, 2016 and is downtrending. It has underperformed by 56.55% the S&P500.

Juno Therapeutics, Inc. is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The company has market cap of $3.27 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. The Company’s product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas.

Investors sentiment increased to 1.11 in 2016 Q4. Its up 0.07, from 1.04 in 2016Q3. It is positive, as 33 investors sold Juno Therapeutics Inc shares while 37 reduced holdings. 23 funds opened positions while 50 raised stakes. 45.31 million shares or 3.22% more from 43.89 million shares in 2016Q3 were reported. Moreover, Caprock Gp has 0.15% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 23,923 shares. Principal Gp, Iowa-based fund reported 11,147 shares. Federated Pa has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). 53,142 were reported by National Bank & Trust Of America Corporation De. Glenmede Tru Co Na reported 150 shares. X Mgmt Ltd Liability Corporation owns 239 shares. Invesco Ltd has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). 90,000 were accumulated by Eventide Asset Mgmt Llc. Utah Retirement holds 0.01% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 11,400 shares. Bank Of New York Mellon Corporation holds 0% in Juno Therapeutics Inc (NASDAQ:JUNO) or 255,636 shares. Bnp Paribas Arbitrage holds 20,331 shares. Blackrock Ltd has invested 0% in Juno Therapeutics Inc (NASDAQ:JUNO). Mitsubishi Ufj & Bk invested in 948,320 shares. Commerzbank Aktiengesellschaft Fi holds 10,181 shares. 250,435 are held by Brown Advisory.

Investors sentiment increased to 1.19 in 2016 Q4. Its up 0.02, from 1.17 in 2016Q3. It is positive, as 38 investors sold BLK shares while 294 reduced holdings. 86 funds opened positions while 303 raised stakes. 127.96 million shares or 1.27% less from 129.61 million shares in 2016Q3 were reported. Bradley Foster Sargent Inc Ct has 1,312 shares. Pittenger And Anderson holds 0.9% of its portfolio in BlackRock, Inc. (NYSE:BLK) for 22,170 shares. The South Carolina-based Greenwood Capital Associate Limited Liability Corporation has invested 1.36% in BlackRock, Inc. (NYSE:BLK). Henderson Grp Inc Public Limited Company reported 0.05% stake. Clinton holds 4,366 shares or 0.1% of its portfolio. First National Trust Co invested in 0.16% or 3,012 shares. Harris Limited Partnership stated it has 0.74% of its portfolio in BlackRock, Inc. (NYSE:BLK). Copeland Management Limited Liability Corporation accumulated 17,132 shares. Canada Pension Plan Invest Board stated it has 0.16% of its portfolio in BlackRock, Inc. (NYSE:BLK). Mitsubishi Ufj Tru & Bk Corporation invested in 244,177 shares. Cap has invested 0% of its portfolio in BlackRock, Inc. (NYSE:BLK). 2,491 are held by Wellington Shields Mgmt Llc. Private Asset Mgmt has 3,443 shares for 0.22% of their portfolio. 4,140 are owned by Lowe Brockenbrough Comm Inc. Earnest Prtnrs Limited Liability Co holds 0% of its portfolio in BlackRock, Inc. (NYSE:BLK) for 65 shares.